Cognyte Software Posts Upbeat Results, Joins AngioDynamics, Allegiant Travel And Other Big Stocks Moving Higher On Wednesday

Benzinga · 04/02 14:13
U.S. stocks were lower, with the Dow Jones index falling over 100 points on Wednesday.
Shares of Cognyte Software Ltd. (NASDAQ:CGNT) rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results.
Cognyte Software posted adjusted earnings of 3 cents per share, beating market estimates of 1 cent per share. The company's quarterly sales came in at $94.505 million versus expectations of $93.154 million.
Cognyte Software shares jumped 22.1% to $10.04 on Wednesday.
Here are some other big stocks recording gains in today's session.
- AngioDynamics, Inc. (NASDAQ:ANGO) shares rose 13.7% to $10.98 after the company reported better-than-expected third-quarter sales results and raised its FY25 guidance above estimates.
- Rocket Companies, Inc. (NYSE:RKT) gained 13.1% to $14.26.
- Cytokinetics, Incorporated (NASDAQ:CYTK) shares rose 12% to $41.99.
- Redfin Corporation (NASDAQ:RDFN) shares surged 11.7% to $10.69.
- CoreWeave, Inc. (NASDAQ:CRWV) gained 10.1% to $57.90.
- Gyre Therapeutics, Inc. (NASDAQ:GYRE) rose 9.8% to $7.04.
- Mr. Cooper Group Inc. (NASDAQ:COOP) surged 9.5% to $136.97.
- Sana Biotechnology, Inc. (NASDAQ:SANA) gained 8.3% to $1.6250.
- Allegiant Travel Company (NASDAQ:ALGT) rose 7.1% to $54.45. Raymond James analyst Savanthi Syth upgraded Allegiant Travel from Outperform to Strong Buy and lowered the price target from $125 to $90.
- Studio City International Holdings Limited (NYSE:MSC) gained 7% to $3.85.
- Arcellx, Inc. (NASDAQ:ACLX) gained 5.9% to $64.28.
- Ciena Corporation (NYSE:CIEN) shares rose 4.6% to $64.34.
- RH (NYSE:RH) rose 3.8% to $248.24 ahead of quarterly earnings.
Now Read This:
Photo via Shutterstock
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.